PMGC Holdings Inc. (NASDAQ: ELAB) announced the initiation of a preclinical study for EL-32, an engineered probiotic candidate developed by its subsidiary NorthStrive Biosciences Inc. The study will evaluate EL-32's potential to preserve lean muscle mass while promoting fat loss, both as a standalone therapy and in combination with GLP-1 weight loss treatments.

The research will utilize a diet-induced obesity mouse model to assess EL-32 across multiple treatment groups, including standalone administration and combination therapy with semaglutide, a GLP-1 receptor agonist. The study will measure changes in body weight and fat mass, preservation of lean muscle mass, glycemic and metabolic markers, and overall body composition.

The preclinical dosing and observation period is expected to occur over several months, followed by data analysis and reporting. Results will inform potential follow-on studies and future development strategy for the therapy.

NorthStrive Biosciences is developing EL-32 to address potential lean body mass loss associated with rapid weight reduction from GLP-1 therapies. The company focuses on developing aesthetic medicines, with EL-22 as its lead asset using an engineered probiotic approach for obesity treatment.

PMGC Holdings Inc. operates as a diversified holding company that manages its portfolio through strategic acquisitions, investments, and development across various industries. The information is based on a company press release statement.